Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma

Muhamed Baljevic, Shadia Zaman, Veerabhadran Baladandayuthapani, Yan Heather Lin, Claudia Morales de Partovi, Zuzana Berkova, Behrang Amini, Sheeba K. Thomas, Jatin J. Shah, Donna M. Weber, Min Fu, Charles S. Cleeland, Xin Shelley Wang, Christine M. Stellrecht, Richard E. Davis, Varsha Gandhi, Robert Z. Orlowski

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences